Champix contains varenicline, a nicotinic acetylcholine receptor partial agonist used to help adults stop smoking. It reduces nicotine cravings and withdrawal symptoms while making cigarettes feel less rewarding.
Champix contains varenicline, a nicotinic acetylcholine receptor partial agonist used to help adults stop smoking.
Champix contains varenicline, a nicotinic acetylcholine receptor partial agonist used to help adults stop smoking.
The European Medicines Agency and the Medicines and Healthcare products Regulatory Agency recognise varenicline as a prescription treatment for smoking cessation when used with behavioural support [1].
This gives varenicline two useful effects:
The European Medicines Agency and the Medicines and Healthcare products Regulatory Agency recognise varenicline as a prescription treatment for smoking cessation when used with behavioural support [1].
Nicotine reaches the brain rapidly and activates nicotinic receptors. This increases dopamine release in reward pathways, reinforcing the urge to smoke. When smoking stops, dopamine stimulation falls, which can produce irritability, restlessness, low mood, poor concentration and strong cravings.
Varenicline binds to the relevant receptors with enough activity to soften this drop in stimulation. It does not reproduce the full nicotine effect. If a person smokes while taking varenicline, the medicine also occupies receptor sites that nicotine would otherwise activate.
The result is a change in the smoking experience rather than an instant disappearance of dependence. Cigarettes may feel less satisfying, while urges become more manageable over time.
This treatment is not for you if:
Varenicline has limited pharmacokinetic interactions because it is not extensively metabolised by liver enzymes. Smoking cessation itself can alter the levels or effects of other medicines. This matters with drugs such as theophylline, warfarin and insulin, because stopping smoking may change their clinical response.
People using insulin or other glucose-lowering treatment can experience changes in blood glucose as smoking stops. Blood glucose monitoring may need closer attention. Patients taking warfarin may require monitoring because the change is linked to stopping smoking rather than a direct varenicline interaction.
Alcohol deserves caution. Some patients report increased intoxication, unusual behaviour or memory gaps while taking varenicline and drinking alcohol. Avoiding alcohol during the adjustment period is a sensible risk-reduction measure.
Champix is not suitable for everyone. A prescriber needs to consider medical history, mental health, kidney function and current medicines before selecting a dose.
The most frequent adverse effect associated with varenicline is nausea. Headache, insomnia, abnormal dreams, dry mouth and gastrointestinal symptoms may also occur. The MHRA product information describes nausea as dose-related in some patients, which is one reason gradual escalation is used [2].
| Possible effect | Practical response |
|---|---|
| Nausea or stomach discomfort | Take the tablet after food with water; report persistent or severe symptoms. |
| Vivid dreams or insomnia | Take the evening dose earlier if the prescribed schedule allows; avoid late caffeine. |
| Headache or dry mouth | Maintain fluid intake and use sugar-free gum for dry mouth. |
Nausea is often strongest early in treatment and may settle as the body adjusts. Persistent vomiting, inability to keep fluids down or severe abdominal symptoms require prompt medical assessment.
Vivid dreams can be memorable and sometimes unpleasant. They do not automatically require treatment cessation, but repeated sleep disruption should be discussed with the prescriber because the schedule or dose may need adjustment.
Mood changes require attention. Stop-smoking treatment can coincide with depression, anxiety or irritability caused by nicotine withdrawal, but new or worsening suicidal thoughts, severe agitation, unusual behaviour, hallucinations or extreme mood changes need urgent medical help.
Severe allergic reactions are rare but require urgent care. Warning signs include swelling of the face, lips or throat, difficulty breathing, widespread blistering rash or faintness.
Champix tablets contain varenicline. The dose is decided individually, taking age, other medicines and health conditions into account. The product is supplied as film-coated tablets. Varenicline acts on the same type of brain receptor stimulated by nicotine, called the α4β2 nicotinic acetylcholine receptor.
The main alternatives differ in whether they provide nicotine, alter reward pathways, or reduce withdrawal through another brain mechanism.
| Treatment approach | Main mechanism and limitation |
|---|---|
| Champix, varenicline | Partial stimulation of nicotinic receptors; nausea and sleep-related effects can occur. |
| Bupropion | Non-nicotine treatment affecting noradrenaline and dopamine; insomnia and seizure risk limit use in some people. |
| Nicotine replacement therapy | Supplies controlled nicotine through patches, gum, lozenges or other forms; correct product selection and regular use affect results. |
Zyban contains bupropion. It does not bind to nicotine receptors in the same way as varenicline. Bupropion can be considered when a non-nicotine approach is preferred, although it is unsuitable for people with a seizure disorder, some eating disorders or specific interacting medicines.
Nicotine replacement therapy can be useful for people who prefer a gradual reduction in nicotine exposure. Combining a long-acting patch with a short-acting product can provide background control and help with sudden cravings, subject to individual prescribing advice.
E-cigarettes occupy a different position. They may reduce exposure to some combustion products when an adult smoker switches completely, but they maintain nicotine dependence and are not identical to a structured varenicline course. Using both cigarettes and e-cigarettes can preserve the smoking routine and limit the health benefit of switching.
Several avoidable errors can make Champix feel less helpful:
One practical point often missed is that craving intensity can rise during a familiar routine even when nicotine withdrawal is improving. This does not necessarily mean the medicine has stopped working. It may indicate that the trigger is behavioural.
Another mistake is using smoking as a test of whether the treatment works. Varenicline is intended to support abstinence, not to make continued smoking risk-free.
Clinicians usually describe varenicline as a receptor-targeted option for adults who want to stop smoking but struggle with strong cravings or previous withdrawal symptoms. It can be useful when the patient understands that tablets support the quit attempt but do not replace preparation and behavioural change.
Doctors also pay attention to psychiatric history. Stable depression or anxiety does not automatically exclude treatment, yet new mood changes require review. A clear plan for contacting the prescriber makes it easier to respond early rather than abandoning treatment abruptly. The best results tend to occur when the patient sets a realistic quit date, takes doses consistently and identifies high-risk routines before stopping. A missed dose, stressful day or single cigarette should be treated as a problem to analyse, not a reason to double the next dose.
A prescriber may also reconsider the treatment if nausea, sleep disturbance or mood symptoms outweigh the benefit. The aim is sustained abstinence with tolerable treatment, not simply completing a tablet course.
Varenicline may cause dizziness, drowsiness or difficulty concentrating in some people. The MHRA product information reviewed in 2025 advises caution until the individual knows how the medicine affects them. Do not drive, cycle on busy roads or operate machinery if you feel impaired, unusually sleepy or unable to concentrate.
Take the missed tablet when remembered unless the next dose is close. Do not take two doses together. NHS smoking-cessation guidance available in 2024 supports returning to the regular schedule rather than compensating with an extra dose. Several missed doses, or a missed dose followed by significant symptoms, may require an individual restart plan.
Regular meals, hydration and moderate physical activity can make withdrawal easier. NHS guidance updated in 2025 supports combining medicine with behavioural support, trigger planning and practical activity. Alcohol can increase the risk of unusual behaviour or memory problems in some people taking varenicline, while excessive caffeine may worsen sleep after smoking stops.
Smoking itself carries substantial pregnancy risks, while varenicline is not routinely used during pregnancy because human safety data are limited. The EMA product information available in 2024 advises an individual assessment of benefit and risk. Breastfeeding also requires a clinical decision because varenicline passes into animal milk and the effect on a breastfed infant is not fully established.
Champix contains varenicline and acts as a partial agonist at α4β2 nicotinic receptors. Bupropion affects noradrenaline and dopamine pathways, while nicotine replacement therapy supplies measured nicotine through products such as patches or gum. NICE guidance from 2025 treats these as different cessation approaches, with choice influenced by medical history, previous attempts and patient preference.
Champix can be taken with or without food, but taking it after food with water may reduce nausea. The EMA product information from 2023 includes food-related administration guidance and supports swallowing the tablet with water. Avoid taking extra tablets when food has been missed; use the prescribed schedule instead.
The usual course lasts 12 weeks, although a prescriber may recommend a longer plan for someone at high risk of relapse. The EMA product information from 2023 recognises that stopping treatment can be followed by increased irritability, low mood, sleep disturbance or renewed cravings in some patients. A gradual reduction may be considered when clinically appropriate, but the patient should not create a tapering schedule independently.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The medicine addresses the receptor response to nicotine. Daily habits address the cues that keep smoking behaviour active. Combining both approaches gives the treatment a stronger practical foundation.
Useful measures include:
Exercise does not need to be intense. A brisk walk can interrupt a craving, reduce restlessness and occupy the hands during a high-risk moment. Sleep can also improve when caffeine is reduced later in the day.
Gareth R., 39 - Bradford, used the titration schedule and stopped smoking during the second week. He reported that cravings were still present after coffee, but they felt shorter and less commanding. Nausea affected the first few mornings and improved after he began taking the tablet after breakfast.
Alan, 61 - London, completed a 12-week course and described the first fortnight as uneven. He noticed vivid dreams and woke earlier than usual, yet found cigarettes less rewarding. A stressful family event led to one cigarette, although he returned to the plan the next day.
Ryan, 42 - Leicester, stopped after several weeks because sleep disruption and irritability became difficult to manage. He had taken the evening dose late and continued drinking alcohol most nights. His experience showed that tolerability can depend on timing and personal habits, not only on the medicine itself.
Neil, 47 - Sunderland, found that the tablets reduced morning cravings but did not remove the urge during work breaks. He replaced those breaks with short walks and completed the planned course. He described the change as gradual rather than dramatic.
